An Extension Study of Venetoclax for Subjects Who Have Completed a Prior Venetoclax Clinical Trial
Active, not recruiting · Phase 3 · NCT03844048
Conditions: Chronic Lymphocytic Leukemia, Acute Myeloid Leukemia, Multiple Myeloma, Non-Hodgkin's Lymphoma, Acute Lymphoblastic Leukemia, Cancer
At a glance
- Research payments reported, 2025
- $17,721
- U.S. investigators named
- 3
- Sites paid
- 3
- Planned or actual enrollment
- 165
About the trial
- Sponsor
- AbbVie
- Tested
- Venetoclax (drug)
- Dates
- Started 2019-09-06; completion 2027-08
- Results posted
- Not yet
The purpose of this extension study is to provide venetoclax and obtain long-term safety data for subjects who continue to tolerate and derive benefit from receiving venetoclax in ongoing studies.
From ClinicalTrials.gov, last updated 2026-05-13. Full record, eligibility and contacts (opens in a new tab)
Industry funding
AbbVie Inc. reported $17,721 in research payments for this study in 2025 (17 payments).
Products named: Venclexta
Research payments usually go to hospitals, universities and research sites to run a study, not to the investigators personally. A payment is not evidence of wrongdoing.
U.S. investigators named on this study
- Sven De Vos, MD Hematology & Oncology · Los Angeles, CA
- Lionel D. Lewis, M.D. Internal Medicine · Lebanon, NH
- Daniel N. Egan, MD Hematology & Oncology · Seattle, WA
Clinicians the company named as principal investigators in its Open Payments reports.
Sites paid to run it
- Swedish Medical Center, WA $8,143
- Dartmouth-Hitchcock Medical Center $7,744
- Resnick Neuropsychiatric Hospital at UCLA, CA $1,833
Sources: CMS Open Payments research payments (program year 2025) and ClinicalTrials.gov, U.S. National Library of Medicine.